EU-Register-Nr.[3]
|
Arzneimittel-Name
|
Wirkstoff(e)
|
ATC-Code
|
Anm.[4]
|
pending
|
Anzupgo neu
|
Delgocitinib
|
D11AH11
|
|
pending
|
Iqirvo neu
|
Elafibranor
|
A05AX06
|
O
|
pending
|
Kayfanda neu
|
Odevixibat
|
A05AX05
|
|
pending
|
Loqtorzi neu
|
Toripalimab
|
L01FF13
|
|
pending
|
Vevizye neu
|
Ciclosporin
|
S01XA18
|
|
pending
|
Vyloy neu
|
Zolbetuximab
|
L01FX31
|
O
|
pending
|
Yuvanci neu
|
Macitentan / Tadalafil
|
C02KX54
|
|
pending
|
Eksunbi neu
|
Ustekinumab
|
L04AC05
|
B
|
pending
|
Fymskina neu
|
Ustekinumab
|
L04AC05
|
B
|
pending
|
Otulfi neu
|
Ustekinumab
|
L04AC05
|
B
|
pending
|
Ituxredi neu
|
Rituximab
|
L01XC02
|
B
|
pending
|
Ranibizumab Midas neu
|
Ranibizumab
|
S01LA04
|
B
|
pending
|
Tuznue neu
|
Trastuzumab
|
L01FD01
|
B
|
pending (negative opinion)
|
Leqembi neu
|
Lecanemab
|
N06DX04
|
|
pending (negative opinion)
|
Masitinib AB Science
|
Masitinib
|
L01EX06
|
|
pending
|
Balversa
|
Erdafitinib
|
L01EN01
|
|
pending
|
Eurneffy
|
Epinephrin
|
C01CA24
|
|
pending
|
mResvia
|
mRNA-Impfstoff
|
J07BX05
|
|
pending
|
Ordspono
|
Odronextamab
|
|
O, C
|
pending
|
Piasky
|
Crovalimab
|
L04AJ07
|
|
pending
|
Tauvid
|
[18F]Flortaucipir
|
V09AX07
|
|
pending
|
Winrevair
|
Sotatercept
|
C02KX06
|
O
|
pending
|
Steqeyma
|
Ustekinumab
|
L04AC05
|
B
|
pending
|
Adzynma
|
Apadamtase alfa / Cinaxadamtase alfa (rADAMTS13)
|
B01AD13
|
E, O
|
pending
|
Akantior
|
Polyhexanid
|
S01AX24
|
O
|
pending
|
Durveqtix
|
Fidanacogen-Elaparvovec
|
|
|
pending
|
GalliaPharm
|
[68Ge]Germaniumchlorid / [68Ga]Galliumchlorid
|
V09X
|
|
pending
|
Avzivi
|
Bevacizumab
|
L01FG01
|
B
|
pending
|
Obgemsa
|
Vibegron
|
G04BD15
|
|
pending (negative opinion)
|
Syfovre
|
Pegcetacoplan
|
S01XA31
|
|
EU/1/24/1829 neu
|
Zegalogue
|
Dasiglucagon
|
H04AA02
|
|
EU/1/24/1833 neu
|
Cejemly
|
Sugemalimab
|
L01FF11
|
|
EU/1/24/1828
|
Ixchiq
|
Chikungunya-Virus (Stamm CHIKV LR2006-OPY1), lebend, attenuiert
|
|
|
EU/1/24/1818
|
Jeraygo
|
Aprocitentan
|
C02KN01
|
|
EU/1/24/1827
|
Fruzaqla
|
Fruquintinib
|
L01EK04
|
|
EU/1/24/1825
|
Tofidence
|
Tocilizumab
|
L04AC07
|
B
|
EU/1/24/1823
|
Wezenla
|
Ustekinumab
|
L04AC05
|
B
|
EU/1/24/1824
|
Altuvoct
|
Efanesoctocog alfa
|
B02BD02
|
O
|
EU/1/24/1820
|
Truqap
|
Capivasertib
|
L01EX27
|
|
EU/1/24/1816
|
Fluenz
|
Influenzavirus (lebend, attenuiert), nasal
|
J07BB03
|
|
EU/1/24/1805
|
Agilus
|
Dantrolen
|
|
H
|
EU/1/23/1783
|
Qalsody
|
Tofersen
|
N07XX22
|
O
|
EU/1/24/1804
|
Neoatricon
|
Dopamin
|
C01CA04
|
H
|
EU/1/24/1798
|
Lytenava
|
Bevacizumab
|
S01LA08
|
|
EU/1/24/1812
|
Wyost
|
Denosumab
|
M05BX04
|
B
|
EU/1/24/1802
|
Fabhalta
|
Iptacopan
|
L04AJ08
|
O
|
EU/1/24/1815
|
Awiqli
|
Insulin icodec
|
A10AE07
|
|
EU/1/24/1817
|
Omlyclo
|
Omalizumab
|
R03DX05
|
B
|
EU/1/24/1813
|
Jubbonti
|
Denosumab
|
M05BX04
|
B
|
EU/1/24/1808
|
Emblaveo
|
Aztreonam / Avibactam
|
J01DF51
|
|
EU/1/24/1796
|
Apremilast Accord
|
Apremilast
|
L04AA32
|
B
|
EU/1/24/1806
|
Celldemic
|
Zoonotischer Influenzaimpfstoff (H5N1) (Oberflächenantigen, inaktiviert, adjuvantiert
|
J07BB02
|
|
EU/1/24/1807
|
Incellipan
|
Pandemischer Influenzaimpfstoff (H5N1) (Oberflächenantigen, inaktiviert, adjuvantiert
|
J07BB02
|
|
EU/1/24/1788
|
Filspari
|
Sparsentan
|
C09XX01
|
O
|
EU/1/24/1797
|
Tizveni
|
Tislelizumab
|
L01FF09
|
|
EU/1/24/1792
|
Voydeya
|
Danicopan
|
L04AJ09
|
O
|
EU/1/24/1800
|
Zynyz
|
Retifanlimab
|
L01FF10
|
O
|
EU/1/24/1801
|
Pyzchiva
|
Ustekinumab
|
L04AC05
|
B
|
EU/1/24/1803
|
Nintedanib Accord
|
Nintedanib
|
L01EX09
|
B
|
pending (re-eaxination after negative opinion)
|
Nezglyal
|
Leriglitazon
|
|
O
|
EU/1/24/1794
|
Exblifep
|
Cefepim / Enmetazobactam
|
J01DE51
|
|
EU/1/24/1793
|
Ryzneuta
|
Efbemalenograstim alfa
|
L03AA1
|
|
EU/1/23/1790
|
Velsipity
|
EtrasimodEU/1/23/1791
|
L04AE05
|
|
EU/1/23/1787
|
Casgevy
|
Exagamglogen-Autotemcel
|
B06AX05
|
O, O, C
|
EU/1/23/1786
|
Skyclarys
|
Omaveloxolon
|
|
O
|
EU/1/23/1782
|
Omjjara
|
Momelotinib
|
|
OOO
|
EU/1/23/1779
|
Rimmyrah
|
Ranibizumab
|
S01LA04
|
B
|
EU/1/23/1780
|
Rystiggo
|
Rozanolixizumab
|
L04AG16
|
O
|
EU/1/23/1784
|
Uzpruvo
|
Ustekinumab
|
L04AC05
|
B
|
EU/1/23/1781
|
Spexotras
|
Trametinib
|
L01EE01
|
O
|
EU/1/23/1744
|
Krazati
|
Adagrasib
|
L01XX77
|
C
|
refused
|
Albrioza
|
Natriumphenylbutyrat / Ursodoxicoltaurin
|
|
O
|
EU/1/23/1775
|
Rezzayo
|
Rezafungin
|
J02AX08
|
O
|
EU/1/23/1774
|
Loargys
|
Pegzilarginase
|
A16AB24
|
E
|
EU/1/23/1776
|
Agamree
|
Vamorolon
|
|
|
pending (2nd negative opinion reg. renewal) [1]
|
Translarna (EU/1/13/902)
|
Ataluren
|
M09AX03
|
O, C
|
nicht erneuert
|
Blenrep (EU/1/20/1474)
|
Belantamab-Mafodotin
|
L01XC39
|
O, C
|
EU/1/23/1773
|
Vueway
|
Gadopiclenol
|
V08CA12
|
|
EU/1/23/1772
|
Elucirem
|
Gadopiclenol
|
V08CA12
|
|
EU/1/23/1771
|
Veoza
|
Fezolinetant
|
G02CX06
|
|
EU/1/23/1770
|
Elrexfio
|
Elranatamab
|
|
C
|
EU/1/23/1764
|
Zilbrysq
|
Zilucoplan
|
L04AJ06
|
(O)
|
EU/1/23/1766
|
Yorvipath
|
Palopegteriparatid
|
H05AA05
|
O
|
EU/1/23/1765
|
Ebglyss
|
Lebrikizumab
|
|
|
EU/1/23/1717
|
Aqumeldi
|
Enalapril
|
C09AA02
|
PUMA
|
EU/1/23/1767
|
Finlee
|
Dabrafenib
|
L01EC02
|
O
|
EU/1/23/1762
|
Herwenda
|
Trastuzumab
|
L01FD01
|
B
|
EU/1/23/1763
|
Catiolanze
|
Latanoprost
|
S01EE01
|
|
EU/1/23/1768
|
Vanflyta (note)
|
Quizartinib
|
L01EX11
|
(O)
|
EU/1/23/1738
|
Jaypirca
|
Pirtobrutinib
|
|
O, C
|
withdrawn
|
Vijoice
|
Alpelisib
|
|
O, W
|
EU/1/23/1761
|
Zoonotic Influenza Vaccine Seqirus
|
Impfstoff gegen zoonotische Influenza (H5N1) (inaktiviert, adjuvantiert)
|
J07BB02
|
|
withdrawn
|
Sugammadex Lorien
|
Sugammadex
|
|
|
EU/1/23/1759
|
Tepkinly
|
Epcoritamab
|
L01FX27
|
O, C
|
EU/1/23/1745
|
Tyruko
|
Natalizumab
|
L04AA23
|
B
|
EU/1/23/1760
|
Apretude
|
Cabotegravir
|
J05AJ04
|
|
EU/1/23/1758
|
Tevimbra
|
Tislelizumab
|
L01FF09
|
O
|
EU/1/23/1757
|
Orserdu
|
Elacestrant
|
L02BA04
|
|
EU/1/23/1756
|
Inaqovi
|
Decitabin / Cedazuridin
|
L01BC58
|
O
|
EU/1/23/1755
|
Litfulo
|
Ritlecitinib
|
L04AF08
|
|
EU/1/23/1754
|
Tyenne
|
Tocilizumab
|
L04AC07
|
B
|
EU/1/23/1751
|
Yesafili
|
Aflibercept
|
S01LA05
|
B
|
EU/1/23/1747
|
Enrylaze
|
Crisantaspase
|
L01XX02
|
|
EU/1/21/1613
|
Lyfnua
|
Gefapixant
|
R05DB29
|
|
withdrawn
|
Jivadco
|
Trastuzumab-Duocarmazin
|
|
|
withdrawn
|
Skycovion
|
GBP510
|
|
|
withdrawn
|
Vivjoa
|
Oteseconazol
|
|
|
EU/1/23/1752
|
Abrysvo
|
RSV-Impfstoff (bivalent, rekombinant)
|
J07BX05
|
A
|
EU/1/23/1748
|
Talvey
|
Talquetamab
|
|
O, C
|
EU/1/23/1750
|
Aquipta
|
Atogepant
|
N02CD07
|
|
EU/1/23/1743
|
Ztalmy
|
Ganaxolon
|
N03AX27
|
O
|
EU/1/23/1746
|
Pylclari
|
Piflufolastat (18F)
|
V09IX16
|
|
withdrawn
|
Lutholaz
|
Pegfilgastrim
|
|
|
refused
|
Sohonos
|
Palovaroten
|
M09AX11
|
O
|
withdrawn
|
Gefzuris
|
Gefapixant
|
R05DB29
|
W
|
withdrawn
|
Jesduvroq
|
Daprodustat
|
B03XA07
|
W
|
EU/1/23/1742
|
Columvi
|
Glofitamab
|
L01FX28
|
O, C
|
EU/1/23/1741
|
Lytgobi
|
Futibatinib
|
L01EN04
|
O, C
|
EU/1/23/1716
|
Camzyos
|
Mavacamten
|
C01EB24
|
|
EU/1/23/1737
|
Opfolda
|
Miglustat
|
A16AX06
|
|
withdrawn
|
Lagevrio
|
Molnupiravir
|
J05AB18
|
W
|
EU/1/23/1740
|
Arexvy
|
RSV-Impfstoff, rekombinant, adjuvantiert
|
J07
|
|
EU/1/23/1730
|
Briumvi
|
Ublituximab
|
L04AG14
|
|
EU/1/23/1736
|
Omvoh
|
Mirikizumab
|
L04AA25
|
|
EU/1/23/1735
|
Epysqli
|
Eculizumab
|
L04AA25
|
B
|
EU/1/23/1731
|
Qaialdo
|
Spironolacton
|
C03DA01
|
WEU
|
EU/1/23/1734
|
Pedmarqsi
|
Natriumthiosulfat
|
|
PUMA
|
EU/1/23/1723
|
Hyftor
|
Sirolimus
|
L04AA
|
O
|
EU/1/23/1728
|
Tibsovo
|
Ivosidenib
|
L01XX62
|
O, O
|
EU/1/23/1724
|
Elfabrio
|
Pegunigalsidase alfa
|
A16AB20
|
O
|
EU/1/23/1725
|
Vafseo
|
Vadadustat
|
B03XA08
|
|
EU/1/23/1722
|
Akeega
|
Niraparib / Abirateronacetat
|
L01XK02
|
|
EU/1/23/1726
|
Opzelura
|
Ruxolitinib
|
L04AA
|
|
EU/1/23/1727
|
Bekemv
|
Eculizumab
|
L04AA25
|
B
|
refused
|
Omblastys
|
Iod(131I)-Omburtamab
|
V10XA
|
O
|
EU/1/23/1709
|
Bimervax
|
COVID-19-Impfstoff (rekombinant, adjuvantiert)
|
J07BN
|
|
withdrawn
|
Tidhesco
|
Ivosidenib
|
L01XX62
|
O, W
|
EU/1/23/1718
|
Sotyktu
|
Deucravacitinib
|
L04AA56
|
|
EU/1/22/1714
|
Pombiliti
|
Cipaglucosidase alfa
|
A16AB23
|
O
|
EU/1/22/1715
|
Hemgenix
|
Etranacogen-Dezaparvovec
|
B06
|
O, C
|
EU/1/22/1713
|
Imjudo
|
Tremelimumab
|
L01FX20
|
|
EU/1/22/1712
|
Tremelimumab AstraZeneca, zurückgezogen 12.10.2023
|
Tremelimumab
|
L01FX20
|
|
EU/1/22/1710
|
Kauliv
|
Teriparatid
|
H05AA02
|
B
|
EU/1/22/1695
|
Zynlonta
|
Loncastuximab-Tesirin
|
L01FX22
|
O, C
|
EU/1/22/1700
|
Ebvallo
|
Tabelecleucel
|
|
E
|
EU/1/22/1706
|
Eladynos
|
Abaloparatid
|
H05AA04
|
|
EU/1/22/1704
|
Livmarli
|
Maralixibat
|
A05AX04
|
E
|
EU/1/22/1703
|
Pluvicto
|
Lutetium(177Lu)vipivotidtetraxetan
|
V10XX05
|
|
EU/1/22/1692
|
Locametz
|
Gozetotid
|
V09IX14
|
|
EU/1/22/1688
|
Spevigo
|
Spesolimab
|
L04AC22
|
C
|
EU/1/22/1699
|
Qdenga
|
Dengue-Virus-Impfstoff, tetravalent (lebend, abgeschwächt)
|
J07BX04
|
|
EU/1/22/1690
|
Mycapssa
|
Octreotid
|
H01CB02
|
O
|
EU/1/22/1697
|
Teriparatide SUN
|
Teriparatid
|
H05AA02
|
|
EU/1/22/1687
|
Enjaymo
|
Sutimlimab
|
L04AA55
|
O
|
EU/1/21/1580
|
VidPrevtyn Beta
|
COVID-19-Impfstoff (rekombinant, adjuvantiert)
|
J07BX03
|
|
EU/1/22/1691
|
Ximluci
|
Ranibizumab
|
S01LA04
|
B
|
EU/1/22/1672
|
Livtencity
|
Maribavir
|
J05AX10
|
O
|
EU/1/22/1662
|
Pyrukynd
|
Mitapivat
|
B06AX04
|
O, C
|
EU/1/22/1694
|
Melatonin Neurim
|
Melatonin
|
N05CH01
|
|
EU/1/22/1689
|
Beyfortus
|
Nirsevimab
|
|
|
EU/1/22/1677
|
Tezspire
|
Tezepelumab
|
R03DX11
|
|
EU/1/22/1676
|
Thalidomide Lipomed
|
Thalidomid
|
L04AX02
|
EU/1/22/1685
|
Mounjaro
|
Tirzepatid
|
A10B
|
|
EU/1/22/1684
|
Nulibry
|
Fosdenopterin
|
A16AX19
|
O, E
|
EU/1/22/1683
|
Vabysmo
|
Faricimab
|
S01L
|
|
EU/1/22/1681
|
Amvuttra
|
Vutrisiran
|
|
O
|
EU/1/22/1680
|
Illuzyce
|
Lutetium(177Lu)chlorid
|
V10X
|
|
EU/1/22/1678
|
Lupkynis
|
Voclosporin
|
L04AD03
|
|
EU/1/22/1679
|
Opdualag
|
Relatlimab / Nivolumab
|
L01XY03
|
|
EU/1/22/1666
|
Celdoxome pegylated liposomal
|
Doxorubicin
|
L01DB01
|
|
EU/1/22/1673
|
Ranivisio
|
Ranibizumab
|
S01LA04
|
B
|
EU/1/22/1670
|
Scemblix
|
Asciminib
|
L01EA06
|
O
|
EU/1/22/1668
|
Roctavian
|
Valoctocogen roxaparvovec
|
B02B02
|
O, C
|
EU/1/22/1675
|
Tecvayli
|
Teclistamab
|
|
O, A, C
|
EU/1/21/1587
|
Rayvow
|
Lasmiditan
|
N02CC08
|
|
EU/1/22/1671
|
Sunlenca
|
Lenacapavir
|
J05AX31
|
|
EU/1/22/1669
|
Pepaxti
|
Melphalanflufenamid
|
L01AA10
|
|
EU/1/22/1667
|
Vegzelma
|
Bevacizumab
|
L01XC07
|
B
|
EU/1/22/1674
|
Vyvgart
|
Efgartigimod alfa
|
L04AA58
|
O
|
EU/1/22/1660
|
Zokinvy
|
Lonafarnib
|
|
O, E
|
EU/1/22/1653
|
Upstaza
|
Eladocagen exuparvovec
|
|
O, E
|
EU/1/22/1664
|
Cevenfacta
|
Eptacog beta (aktiviert)
|
B02BD08
|
|
EU/1/22/1657
|
Kinpeygo
|
Budesonid
|
|
O, C
|
EU/1/22/1656
|
Ertapenem SUN
|
Ertapenem
|
J01DH03
|
|
EU/1/22/1659
|
Xenpozyme
|
Olipudase alfa
|
|
O
|
EU/1/21/1579
|
Nexviadyme
|
Avalglucosidase alfa
|
|
|
EU/1/21/1624
|
COVID-19 Vaccine Valneva (inactiviert, adjuvantiert) zurückgezogen am 10.12.2023
|
COVID-19-Impfstoff (inaktiviert, adjuvantiert, adsorbiert)
|
J07BX03
|
W
|
EU/1/22/1652
|
Filsuvez
|
Birkenrindenextrakt
|
D03AX13
|
O
|
EU/1/22/1650
|
Tabrecta
|
Capmatinib
|
|
|
EU/1/21/1606
|
Yselty
|
Linzagolix-Cholin
|
|
|
EU/1/22/1649
|
Lunsumio
|
Mosunetuzumab
|
L01XC
|
O, C
|
EU/1/22/1629
|
Zolsketil pegylated liposomal
|
Doxorubicin
|
L01DB01
|
|
EU/1/22/1648
|
Carvykti
|
Ciltacabtagen autoleucel
|
|
O, C
|
EU/1/22/1647
|
Camcevi
|
Leuprorelin
|
L02AE02
|
|
EU/1/22/1642
|
Orgovyx
|
Relugolix
|
L02BX04
|
|
EU/1/22/1638
|
Quviviq
|
Daridorexant
|
|
|
refused
|
IPIQUE
|
Bevacizumab
|
S01LA04
|
|
EU/1/21/1602
|
Uplizna
|
Inebilizumab
|
L04AA47
|
|
EU/1/22/1644
|
Inpremzia (zurückgezogen am 04.04.2023)
|
Insulin human (rDNA)
|
A10AB01
|
B
|
EU/1/22/1643
|
Kapruvia
|
Difelikefalin
|
V03AX04
|
|
EU/1/22/1641
|
PreHevbri
|
Hepatitis-B-Oberflächenantigen (Hepatitis-B-Impfstoff, rekombinant, adsorbiert)
|
J07BC01
|
|
EU/1/22/1645
|
Vydura
|
Rimegepant
|
N02CD
|
|
EU/1/22/1639
|
Truvelog Mix 30, zurückgezogen 25.01.2024
|
Insulin aspart
|
A10AD05
|
B
|
EU/1/21/1615
|
Padcev
|
Enfortumab vedotin
|
L01FX13
|
|
EU/1/22/1631
|
Breyanzi
|
Lisocabtagen maraleucel
|
L01
|
|
EU/1/22/1630
|
Kimmtrak
|
Tebentafusp
|
|
O
|
EU/1/22/1632
|
Stimufend
|
Pegfilgrastim
|
L03AA13
|
B
|
EU/1/22/1651
|
Evusheld
|
Tixagevimab / Cilgavimab
|
|
|
EU/1/22/1628
|
Sondelbay
|
Teriparatid
|
H05AA02
|
B
|
EU/1/21/1578
|
Ontilyv
|
Opicapon
|
N04BX04
|
|
EU/1/21/1620
|
Sapropterin Dipharma
|
Sapropterin
|
A16AX07
|
|
EU/1/21/1616
|
Kerendia
|
Finerenon
|
C03DA05
|
|
EU/1/21/1596
|
Tepmetko
|
Tepotinib
|
L01EX21
|
|
EU/1/21/1623
|
Saphnelo
|
Anifrolumab
|
L04AA
|
|
EU/1/21/1622
|
Oxbryta
|
Voxelotor
|
B06AX03
|
O
|
EU/1/21/1621
|
Okedi
|
Risperidon
|
N05AX08
|
|
EU/1/21/1617
|
Ngenla
|
Somatrogon
|
H01AC08
|
O
|
EU/1/21/1612
|
Apexxnar
|
Pneumokokken-Konjugatimpfstoff (20-valent, adsorbiert)
|
J07AL02
|
|
EU/1/22/1625
|
Paxlovid
|
Nirmatrelvir / Ritonavir
|
|
C
|
EU/1/21/1599
|
Vyepti
|
Eptinezumab
|
N02CD05
|
|
EU/1/21/1605
|
Tavneos
|
Avacopan
|
|
O, O
|
EU/1/21/1607
|
Lonapegsomatropin Ascendis Pharma
|
Lonapegsomatropin
|
|
O
|
EU/1/21/1586
|
Voraxaze
|
Glucarpidase
|
V03AF09
|
O, E
|
EU/1/21/1604
|
Riltrava Aerosphere
|
Formoterol / Glycopyrroniumbromid / Budesonid
|
R03AL11
|
|
EU/1/21/1608
|
Wegovy
|
Semaglutid
|
A10BJ06
|
|
EU/1/21/1603
|
Lumykras
|
Sotorasib
|
L01XX73
|
|
EU/1/21/1600
|
Tecovirimat SIGA
|
Tecovirimat
|
J05AX24
|
|
refused
|
Nouryant
|
Istradefyllin
|
N04
|
|
EU/1/21/1618
|
Nuvaxovid
|
COVID-19-Impfstoff (rekombinant, adjuvantiert)
|
J07BX03
|
C
|
EU/1/21/1562
|
Xevudy
|
Sotrovimab
|
J06BD05
|
|
EU/1/21/1595
|
Aspaveli
|
Pegcetacoplan
|
L04AA54
|
O
|
EU/1/21/1591
|
Vaxneuvance
|
Pneumokokken-Konjugatimpfstoff (15‑valent, adsorbiert)
|
J07AL02
|
|
EU/1/21/1594
|
Rybrevant
|
Amivantamab
|
L01FX18
|
C
|
EU/1/21/1593
|
Cibinqo
|
Abrocitinib
|
D11AH08
|
|
EU/1/21/1582
|
Artesunate Amivas
|
Artesunat
|
P01BE03
|
O
|
EU/1/21/1592
|
Trodelvy
|
Sacituzumab-Govitecan
|
L01FX17
|
|
EU/1/21/1576
|
Brukinsa
|
Zanubrutinib
|
L01EL03
|
|
EU/1/21/1569
|
Qinlock
|
Ripretinib
|
L01EX19
|
O
|
EU/1/21/1555
|
Gavreto
|
Pralsetinib
|
L01EX23
|
C
|
EU/1/21/1590
|
Libmyris
|
Adalimumab
|
L04AB04
|
B
|
EU/1/21/1589
|
Hukyndra
|
Adalimumab
|
L04AB04
|
B
|
EU/1/21/1585
|
Vumerity
|
Diroximelfumarat
|
L04AX09
|
|
refused
|
Raylumis
|
Tanezumab
|
N02
|
|
EU/1/21/1601
|
Ronapreve
|
Casirivimab / Imdevimab
|
J06BD
|
|
EU/1/21/1597
|
Regkirona
|
Regdanvimab
|
J06BB
|
|
EU/1/21/1546
|
Ozawade
|
Pitolisant
|
N07XX11
|
|
EU/1/21/1577
|
Voxzogo
|
Vosoritid
|
M05BX07
|
O
|
EU/1/21/1570
|
Minjuvi
|
Tafasitamab
|
L01FX12
|
O, C
|
EU/1/21/1575
|
Bimzelx
|
Bimekizumab
|
L04AC21
|
|
EU/1/21/1572
|
Byooviz
|
Ranibizumab
|
S01LA04
|
B
|
EU/1/21/1574
|
Evrenzo
|
Roxadustat
|
B03XA05
|
|
EU/1/21/1539
|
Abecma
|
Idecabtagen vicleucel
|
L01
|
O, C
|
EU/1/21/1565
|
Ryeqo
|
Relugolix / Estradiol / Norethisteronacetat
|
H01CC54
|
|
EU/1/21/1561
|
Verquvo
|
Vericiguat
|
C01DX22
|
|
EU/1/21/1566
|
Bylvay
|
Odevixibat
|
|
O, E
|
EU/1/21/1564
|
Imcivree
|
Setmelanotid
|
A08AA12
|
O, O, W
|
EU/1/21/1558
|
Klisyri
|
Tirbanibulin
|
D06BX03
|
|
EU/1/21/1563
|
Skysona (zurückgezogen 18.11.2021)
|
Elivaldogen autotemcel
|
N07
|
|
EU/1/21/1559
|
Enspryng
|
Satralizumab
|
L04AC19
|
O
|
EU/1/21/1557
|
Jayempi
|
Azathioprin
|
L04AX01
|
|
EU/1/21/1556
|
Onureg
|
Azacitidin
|
L01BC07
|
|
EU/1/21/1552
|
Koselugo
|
Selumetinib
|
|
O, C
|
EU/1/21/1554
|
Adtralza
|
Tralokinumab
|
D11AH07
|
|
EU/1/21/1551
|
Evkeeza
|
Evinacumab
|
C10AX
|
E
|
EU/1/21/1549
|
Efmody
|
Hydrocortison
|
H02AB09
|
|
EU/1/21/1550
|
Ponvory
|
Ponesimod
|
L04AA50
|
|
EU/1/21/1542
|
Copiktra
|
Duvelisib
|
L01EM04
|
|
EU/1/21/1548
|
Lydisilka
|
Drospirenon / Estetrol
|
G03AA18
|
|
EU/1/21/1547
|
Drovelis
|
Drospirenon / Estetrol
|
G03AA18
|
|
EU/1/20/1517
|
Sibnayal
|
Kaliumcitrat / Kaliumhydrogencarbonat
|
A12BA30
|
|
EU/1/21/1544
|
Orladeyo
|
Berotralstat
|
B06AC06
|
|
EU/1/21/1538
|
Jemperli
|
Dostarlimab
|
L01FF07
|
C
|
EU/1/20/1516
|
Lextemy (zurückgezogen 21.06.2021)
|
Bevacizumab
|
L01XC07
|
B
|
EU/1/20/1515
|
Abevmy
|
Bevacizumab
|
L01XC07
|
B
|
EU/1/20/1501
|
Sogroya
|
Somapacitan
|
H01AC07
|
O
|
EU/1/21/1534
|
BroPair Spiromax
|
Salmeterol / Fluticasonpropionat
|
R03AK06
|
|
EU/1/21/1533
|
Seffalair Spiromax
|
Salmeterol / Fluticasonpropionat
|
R03AK06
|
|
EU/1/21/1530
|
Ontozry
|
Cenobamat
|
N03AX25
|
|
EU/1/21/1537
|
Nexpovio
|
Selinexor
|
L01XX66
|
|
EU/1/21/1535
|
Pemazyre
|
Pemigatinib
|
|
O, O, C
|
EU/1/21/1532
|
Kesimpta
|
Ofatumumab
|
L04AA52
|
|
EU/1/21/1531
|
Evrysdi
|
Risdiplam
|
M09AX10
|
O, A
|
EU/1/20/1509
|
Oyavas
|
Bevacizumab
|
L01FG01
|
B
|
EU/1/21/1525
|
Jcovden
|
COVID-19-Impfstoff (Ad26.COV2-S [rekombinant])
|
J07BX03
|
C
|
EU/1/20/1527
|
Retsevmo
|
Selpercatinib
|
L01EX22
|
C
|
EU/1/20/1526
|
Tuksya
|
Tucatinib
|
L01EH03
|
|
EU/1/20/1523
|
Ogluo
|
Glucagon
|
H04AA01
|
|
EU/1/20/1513
|
Yuflyma
|
Adalimumab
|
L04AB04
|
B
|
EU/1/20/1522
|
Lumoxiti (zurückgezogen 23.07.2021)
|
Moxetumomab pasudotox
|
L01X
|
O
|
EU/1/20/1514
|
Inrebic
|
Fedratinib
|
L01EJ02
|
O, O, O
|
EU/1/20/1506
|
Kirsty
|
Insulin aspart
|
A10AB05
|
B
|
EU/1/20/1518
|
Rukobia
|
Fostemsavir
|
J05AX29
|
|
EU/1/20/1529
|
Vaxzevria, zurückgezogen gemäß Bescheid 27.03.2024
|
COVID-19-Impfstoff (ChAdOx1-S [rekombinant])
|
J07BX03
|
C, W
|
EU/1/20/1508
|
Enhertu
|
Trastuzumab deruxtecan
|
L01XC
|
C
|
EU/1/20/1503
|
Heplisav B
|
Hepatitis-B-Oberflächenantigen (Hepatitis-B-Impfstoff, rekombinant, adjuvantiert)
|
J07BC01
|
|
EU/1/20/1499
|
Onbevzi, zurückgezogen 11.12.2023
|
Bevacizumab
|
L01FG01
|
B, W
|
EU/1/20/1504
|
Elzonris
|
Tagraxofusp
|
L01XX67
|
O, E
|
EU/1/20/1502
|
Roclanda
|
Tanoprost / Netarsudil
|
S01EE51
|
|
EU/1/20/1500
|
Xofluza
|
Baloxavir marboxil
|
J05AX25
|
|
refused
|
Gamifant
|
Emapalumab
|
L04AA39
|
O
|
EU/1/20/1507
|
Spikevax
|
Elasomeran, COVID-19 mRNA-Impfstoff (nukleosidmodifiziert)]
|
J07BX03
|
C
|
EU/1/20/1528
|
Comirnaty
|
Tozinameran, COVID-19 mRNA-Impfstoff (nukleosidmodifiziert)
|
J07BX03
|
C
|
EU/1/20/1497
|
Phesgo
|
Pertuzumab / Trastuzumab
|
L01XY02
|
|
EU/1/20/1498
|
Trixeo Aerosphere
|
Formoterol / Glycopyrroniumbromid / Budesonid
|
R03AL11
|
|